专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2015142675A3 TREATMENT OF CANCER USING CHIMERIC ANTIGEN RECEPTOR 审中-公开
标题翻译：使用CHIMERIC抗原受体治疗癌症
公开(公告)号：WO2015142675A3
公开(公告)日：2015-11-12
申请号：PCT/US2015020606
申请日：2015-03-13
申请人： NOVARTIS AG , UNIV PENNSYLVANIA , LOEW ANDREAS , MILONE MICHAEL C , POWELL DANIEL J , ZHAO YANGBING
发明人： LOEW ANDREAS , MILONE MICHAEL C , POWELL DANIEL J , ZHAO YANGBING
IPC分类号： A61K39/00 , A61K39/12 , A61K39/39 , C07K14/705 , C07K14/725 , C07K16/28 , C07K16/32 , C12N5/0783
CPC分类号： C12N5/0638 , A61K39/0011 , A61K39/39 , A61K39/3955 , A61K2039/505 , A61K2039/5156 , A61K2039/55527 , C07K16/28 , C07K16/2863 , C07K16/30 , C07K16/32 , C07K2317/22 , C07K2317/569 , C07K2317/622 , C07K2317/77 , C07K2317/92 , C07K2319/00 , C07K2319/03 , C07K2319/32 , C12N5/0636 , C12N2510/00 , A61K2300/00
摘要： The invention provides compositions and methods for treating diseases associated with expression of a cancer associated antigen as described herein. The invention also relates to chimeric antigen receptor (CAR) specific to a cancer associated antigen as described herein, vectors encoding the same, and recombinant T cells comprising the CARs of the present invention. The invention also includes methods of administering a genetically modified T cell expressing a CAR that comprises an antigen binding domain that binds to a cancer associated antigen as described herein.
摘要翻译：本发明提供用于治疗与本文所述的癌相关抗原表达相关的疾病的组合物和方法。本发明还涉及本文所述的与癌症相关抗原特异性的嵌合抗原受体（CAR），编码本发明的载体和包含本发明的CAR的重组T细胞。本发明还包括施用表达CAR的经遗传修饰的T细胞的方法，所述T细胞包含结合如本文所述的癌症相关抗原的抗原结合结构域。

2. 发明申请

WO2015142675A8 TREATMENT OF CANCER USING CHIMERIC ANTIGEN RECEPTOR 审中-公开
标题翻译：使用CHIMERIC抗原受体治疗癌症
公开(公告)号：WO2015142675A8
公开(公告)日：2016-10-20
申请号：PCT/US2015020606
申请日：2015-03-13
申请人： NOVARTIS AG , UNIV PENNSYLVANIA , LOEW ANDREAS , MILONE MICHAEL C , POWELL DANIEL J , ZHAO YANGBING
发明人： LOEW ANDREAS , MILONE MICHAEL C , POWELL DANIEL J , ZHAO YANGBING
IPC分类号： A61K39/00 , A61K39/12 , A61K39/39 , C07K14/705 , C07K14/725 , C07K16/28 , C07K16/32 , C12N5/0783
CPC分类号： C12N5/0638 , A61K39/0011 , A61K39/39 , A61K39/3955 , A61K2039/505 , A61K2039/5156 , A61K2039/55527 , C07K16/28 , C07K16/2863 , C07K16/30 , C07K16/32 , C07K2317/22 , C07K2317/569 , C07K2317/622 , C07K2317/77 , C07K2317/92 , C07K2319/00 , C07K2319/03 , C07K2319/32 , C12N5/0636 , C12N2510/00 , A61K2300/00
摘要： The invention provides compositions and methods for treating diseases associated with expression of a cancer associated antigen as described herein. The invention also relates to chimeric antigen receptor (CAR) specific to a cancer associated antigen as described herein, vectors encoding the same, and recombinant T cells comprising the CARs of the present invention. The invention also includes methods of administering a genetically modified T cell expressing a CAR that comprises an antigen binding domain that binds to a cancer associated antigen as described herein.
摘要翻译：本发明提供用于治疗与本文所述的癌相关抗原表达相关的疾病的组合物和方法。本发明还涉及本文所述的与癌症相关抗原特异性的嵌合抗原受体（CAR），编码本发明的载体和包含本发明的CAR的重组T细胞。本发明还包括施用表达CAR的经遗传修饰的T细胞的方法，所述T细胞包含结合如本文所述的癌症相关抗原的抗原结合结构域。

3. 发明申请

WO2014130635A8 EFFECTIVE TARGETING OF PRIMARY HUMAN LEUKEMIA USING ANTI-CD123 CHIMERIC ANTIGEN RECEPTOR ENGINEERED T CELLS 审中-公开
标题翻译：使用抗CD123阴性抗原受体工程化T细胞的主要人类白血病的有效指标
公开(公告)号：WO2014130635A8
公开(公告)日：2015-05-14
申请号：PCT/US2014017328
申请日：2014-02-20
申请人： NOVARTIS AG , UNIV PENNSYLVANIA , BROGDON JENNIFER , GILL SAAR , JUNE CARL H , KALOS MICHAEL D , LOEW ANDREAS , SCHOLLER JOHN
发明人： BROGDON JENNIFER , GILL SAAR , JUNE CARL H , KALOS MICHAEL D , LOEW ANDREAS , SCHOLLER JOHN
IPC分类号： C07K16/28 , A61K39/00 , C07K14/705 , C07K14/725
CPC分类号： C07K16/2866 , A61K35/17 , A61K35/28 , A61K38/1774 , A61K39/3955 , A61K2039/505 , A61K2039/507 , A61K2039/5158 , C07K14/7051 , C07K14/70517 , C07K16/2803 , C07K2317/24 , C07K2317/53 , C07K2317/622 , C07K2317/73 , C07K2319/00 , C07K2319/30 , C07K2319/33
摘要： The invention provides compositions and methods for treating leukemia, for example, acute myeloid leukemia (AML) and B-cell acute lymphoid leukemia (B-ALL). The invention also relates to at least one chimeric antigen receptor (CAR) specific to CD 123, vectors comprising the same, and recombinant T cells comprising the CD 123 CAR. The invention also includes methods of administering a genetically modified T cell expressing a CAR that comprises a CD 123 binding domain. The invention also includes methods of bone marrow ablation for use in treatments necessitating bone marrow reconditioning or transplant.
摘要翻译：本发明提供了用于治疗白血病的组合物和方法，例如急性骨髓性白血病（AML）和B细胞急性淋巴细胞白血病（B-ALL）。本发明还涉及至少一种对CD123特异性的嵌合抗原受体（CAR），包含其的载体和包含CD123 CAR的重组T细胞。本发明还包括施用表达包含CD123结合结构域的CAR的遗传修饰的T细胞的方法。本发明还包括用于需要骨髓修复或移植的治疗中的骨髓消融的方法。

4. 发明申请

WO2016044605A1 TARGETING CYTOTOXIC CELLS WITH CHIMERIC RECEPTORS FOR ADOPTIVE IMMUNOTHERAPY 审中-公开
标题翻译：靶向用于自体免疫球蛋白受体的细胞因子
公开(公告)号：WO2016044605A1
公开(公告)日：2016-03-24
申请号：PCT/US2015050715
申请日：2015-09-17
申请人： BEATTY GREGORY , ENGELS BORIS , IDAMAKANTI NEERAJA , JUNE CARL H , LOEW ANDREAS , MILONE MICHAEL C , SONG HUIJUAN , WANG ENXIU , WU QILONG
发明人： ENGELS BORIS , IDAMAKANTI NEERAJA , JUNE CARL H , LOEW ANDREAS , MILONE MICHAEL C , SONG HUIJUAN , WANG ENXIU , WU QILONG
IPC分类号： C07K16/28 , C07K14/705 , C07K14/735 , C07K16/30
CPC分类号： C07K16/28 , A61K35/17 , C07K14/705 , C07K14/70503 , C07K14/7051 , C07K14/70535 , C07K14/70539 , C07K14/7056 , C07K14/70596 , C07K16/30 , C07K2317/21 , C07K2317/56 , C07K2317/565 , C07K2317/622 , C07K2317/74 , C07K2319/02 , C07K2319/03 , C07K2319/70 , C07K2319/74 , C12N5/0636 , C12N2510/00
摘要： The present invention provides compositions and methods for regulating the specificity and activity of immune effector cells for use in immunotherapy. In one embodiment, the invention provides a type of chimeric antigen receptor (CAR) wherein the CAR is termed a "NKR-CAR" which is a CAR design comprising a component of a receptor naturally found on natural killer (NK) cells. In one embodiment, the NK receptor includes but is not limited to a naturally occurring activating and inhibitory receptor of NK cells known as a killer cell immunoglobulin-like receptor (KIR).
摘要翻译：本发明提供了用于调节用于免疫治疗的免疫效应细胞的特异性和活性的组合物和方法。在一个实施方案中，本发明提供了一种嵌合抗原受体（CAR），其中CAR被称为“NKR-CAR”，其是包含天然杀伤（NK）细胞天然存在的受体成分的CAR设计。在一个实施方案中，NK受体包括但不限于被称为杀伤细胞免疫球蛋白样受体（KIR）的NK细胞的天然存在的活化和抑制性受体。

5. 发明申请

WO2011051327A3 SMALL ANTIBODY-LIKE SINGLE CHAIN PROTEINS 审中-公开
标题翻译：小型抗体样单链蛋白
公开(公告)号：WO2011051327A3
公开(公告)日：2011-06-30
申请号：PCT/EP2010066243
申请日：2010-10-27
申请人： NOVARTIS AG , LOEW ANDREAS
发明人： LOEW ANDREAS
IPC分类号： C07K16/00
CPC分类号： C07K16/468 , C07K16/00 , C07K16/081 , C07K16/1232 , C07K16/14 , C07K16/16 , C07K16/464 , C07K2317/22 , C07K2317/569
摘要： The present invention provides a "ASCP-body" that comprises a bottomside epitope binding domain ("BEBD") comprising four Bottomside Binding Regions (BBR1, BBR2, BBR3, and BBR4). This epitope binding domain is in addition to the topside epitope binding domain (TEBD) formed by the three Complementarity Determining Regions (CDR1, CDR2, and CDR3). The invention encompasses mono-specific, bi-specific and multi-specific, and mono-valent, bi-valent and multi-valent ASCP-bodies. The invention also encompasses fusion proteins in which one or more ASCP-bodies with a BEBD is conjugated to one or more ASCP-bodies with a BEBD and, optionally, a TEBD; to one or more ASCP- bodies with a TEBD and, optionally, a BEBD; or to one or more non-ASCP-body entity(ies). The various ASCP-bodies in the bi-specific and multi-specific ASCP-bodies and fusion proteins may all bind to the same epitopes or antigens or may bind to different epitopes or antigens.
摘要翻译：本发明提供了包含含有四个底部结合区（BBR1，BBR2，BBR3和BBR4）的底侧表位结合结构域（“BEBD”）的“ASCP-体”。该表位结合域除了由三个互补决定区（CDR1，CDR2和CDR3）形成的上游表位结合域（TEBD）之外。本发明包括单特异性，双特异性和多特异性以及单价，二价和多价ASCP体。本发明还包括融合蛋白，其中一个或多个具有BEBD的ASCP-体与BEBD和任选的TEBD缀合至一个或多个ASCP-体; 到一个或多个具有TEBD和可选的BEBD的ASCP体; 或一个或多个非ASCP机构实体。双特异性和多特异性ASCP体和融合蛋白中的各种ASCP体可全部结合相同的表位或抗原或可结合不同的表位或抗原。

6. 发明申请

WO2016098078A3 DIMERIZATION SWITCHES AND USES THEREOF 审中-公开
标题翻译：二化化开关及其用途
公开(公告)号：WO2016098078A3
公开(公告)日：2016-10-27
申请号：PCT/IB2015059796
申请日：2015-12-18
申请人： NOVARTIS AG , LOEW ANDREAS , VASH BRIAN
发明人： LOEW ANDREAS , VASH BRIAN
IPC分类号： C12N15/62 , C12N9/12 , C12N9/90
CPC分类号： C12N9/90 , C07K2319/09 , C07K2319/70 , C07K2319/81 , C12N9/12 , C12Y207/11001 , C12Y502/01008
摘要： The present invention provides gene editing systems comprising gene editing dimerization switches comprising a first and second gene editing switch domain that allow for the regulation of a gene editing function by the introduction, e.g., administration, of a gene editing dimerization molecule having the ability to bring together a first gene editing switch domain and a second gene editing switch domain. A regulated gene editing function provides, e.g., less off-target side effects, and increases the therapeutic window. The present invention also provides improved FKBP/FRB-based dimerization switches wherein the FRB switch domain or the FKBP switch domain, or both the FRB and FKBP switch domains, comprise one or more mutations that optimize performance, e.g., that alter, e.g., enhance the formation of a complex between the first switch domain, the second switch domain, and the dimerization molecule, rapamycin, or a rapalog, e.g., RAD001.
摘要翻译：本发明提供了基因编辑系统，其包含基因编辑二聚化开关，所述基因编辑二聚化开关包含第一和第二基因编辑开关结构域，所述第一和第二基因编辑开关结构域允许通过引入（例如施用）编码二聚化分子的基因来调节基因编辑功能，一起构成第一基因编辑开关域和第二基因编辑开关域。受管理的基因编辑功能提供了例如更少的脱靶副作用，并增加了治疗窗口。本发明还提供了改进的基于FKBP / FRB的二聚化开关，其中FRB开关结构域或FKBP开关结构域或FRB和FKBP开关结构域两者包含一个或多个优化性能的突变，例如改变例如增强第一开关结构域，第二开关结构域和二聚化分子雷帕霉素或雷帕霉素例如RAD001之间形成复合物。

7. 发明申请

WO2014043509A3 SINGLE DOMAIN ANTIBODY WITH C-TERMINAL MODIFICATION 审中-公开
标题翻译：具有C末端修饰的单域抗体
公开(公告)号：WO2014043509A3
公开(公告)日：2014-05-30
申请号：PCT/US2013059721
申请日：2013-09-13
申请人： NOVARTIS AG , LOEW ANDREAS , EBERSBACH HILMAR
发明人： LOEW ANDREAS , EBERSBACH HILMAR
IPC分类号： C07K16/00 , A61P43/00 , C07K16/18
CPC分类号： G01N33/5306 , A61K2039/505 , C07K16/00 , C07K16/18 , C07K2317/21 , C07K2317/40 , C07K2317/569
摘要： The disclosure pertains to an antigen binding domain (ABD) comprising a C-terminal modification, an N-terminal modification, or a C + N terminal modification, wherein the C-terminal modification, N-terminal modification, or C + N terminal modification comprises the addition or deletion of at least one amino acid residue such that the addition or deletion of at least one amino acid residue to the ABD eliminates the interaction of a pre-existing antibody with the ABD without interfering with the binding of the ABD with its target.
摘要翻译：本公开涉及包含C-末端修饰，N-末端修饰或C + N末端修饰的抗原结合结构域（ABD），其中C-末端修饰，N-末端修饰或C + N末端修饰包括添加或缺失至少一个氨基酸残基，使得向ABD添加或缺失至少一个氨基酸残基消除了先前存在的抗体与ABD的相互作用，而不会干扰ABD与其结合目标。

8. 发明申请

WO2013049234A2 DUAL FUNCTION PROTEINS FOR TREATING METABOLIC DISORDERS 审中-公开
标题翻译：用于治疗代谢障碍的双功能蛋白
公开(公告)号：WO2013049234A2
公开(公告)日：2013-04-04
申请号：PCT/US2012057371
申请日：2012-09-26
申请人： NOVARTIS AG , IRM LLC , BOETTCHER BRIAN R , CAPLAN SHARI L , CELLITTI SUSAN E , DANIELS DOUGLAS S , HAMAMATSU NORIO , GEIERSTANGER BERNHARD HUBERT , LICHT STUART , LOEW ANDREAS , WELDON STEPHEN CRAIG
发明人： BOETTCHER BRIAN R , CAPLAN SHARI L , CELLITTI SUSAN E , DANIELS DOUGLAS S , HAMAMATSU NORIO , GEIERSTANGER BERNHARD HUBERT , LICHT STUART , LOEW ANDREAS , WELDON STEPHEN CRAIG
IPC分类号： C07K14/435
CPC分类号： C07K14/605 , C07K14/50 , C07K2319/00 , C07K2319/30 , C07K2319/75
摘要： The present invention relates to the identification of new proteins comprising fibroblast growth factor 21 (FGF21) and other metabolic regulators, including variants thereof, known to improve metabolic profiles in subjects to whom they are administered. Also disclosed are methods for treating FGF21-associated disorders, GLP-1-associated disorders, and Exendin-4-associated disorders, including metabolic conditions.
摘要翻译：本发明涉及鉴定包含成纤维细胞生长因子21（FGF21）和其他代谢调节剂（包括其变体）的新蛋白质，已知其可改善其给药对象的代谢特征。还公开了治疗FGF21相关疾病，GLP-1相关疾病和毒蜥外泌肽-4相关疾病（包括代谢病症）的方法。

9. 发明申请

WO2012016245A3 FIBRONECTIN CRADLE MOLECULES AND LIBRARIES THEREOF 审中-公开
标题翻译： FIBRONECTIN CRADLE分子及其文库
公开(公告)号：WO2012016245A3
公开(公告)日：2012-08-09
申请号：PCT/US2011046160
申请日：2011-08-01
申请人： NOVARTIS AG , UNIV CHICAGO , LOEW ANDREAS , VASH BRIAN EDWARD , KOIDE SHOHEI , WOJCIK JOHN BERNARD , KOIDE AKIKO , GILBRETH RYAN NICHOLAS
发明人： LOEW ANDREAS , VASH BRIAN EDWARD , KOIDE SHOHEI , WOJCIK JOHN BERNARD , KOIDE AKIKO , GILBRETH RYAN NICHOLAS
IPC分类号： C07K16/18 , C07K16/40 , C07K16/42
CPC分类号： C07K14/78 , C07K16/18 , C07K16/40 , C07K16/42 , C07K2317/34 , C07K2318/20
摘要： The here described invention discloses a combination of a top and bottom loop binder library using the CD and the FG loops of a number of Fnlll domains (Fnlll) (e.g., Fnlll7, Fnlll10 and Fnlll14) together with the surface exposed residues of the beta-sheet. The invention also pertains to a method of forming a library of Fnlll domain polypeptides useful in screening for the presence of one or more polypeptides having a selected binding or enzymatic activity.
摘要翻译：这里描述的发明公开了使用CD和许多FnIII结构域（FnIII）（例如FnIII 17，FnIII10和FnIII 14）的FG环连同β-半乳糖苷酶的表面暴露残基的顶部和底部环结合文库的组合，片。本发明还涉及形成用于筛选具有选择的结合或酶活性的一种或多种多肽的存在的FnIII结构域多肽文库的方法。

10. 发明申请

WO2004063938A3 METHOD FOR CREATING A HISTOGRAM 审中-公开
公开(公告)号：WO2004063938A3
公开(公告)日：2004-10-21
申请号：PCT/EP0314898
申请日：2003-12-24
申请人： THOMSON LICENSING SA , LOEW ANDREAS
发明人： LOEW ANDREAS
IPC分类号： G06F17/18
CPC分类号： G06F17/18
摘要： The invention relates to a method for creating a histogram representing the distribution of supplied quantities which are associated with supplied values within a pre-determined value range, said value range being divided into pre-determined partial ranges which are defined by supporting values. For values which lie between a supporting value and an adjacent supporting value, division factors are calculated according to the position thereof. The quantities are divided according to the respective division factors between the respective supporting value and the adjacent supporting value, and are separately accumulated according to supporting values. The accumulated values are divided by the number of division factors which are respectively separately accumulated according to supporting values.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式